Mid-cap Health Care company Bio-Techne Corp has logged a 0.2% change today on a trading volume of 168,791. The average volume for the stock is 2,272,263.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. Based in Minneapolis, United States the company has 3,100 full time employees and a market cap of $8,766,797,824. Bio-Techne Corp currently offers its equity investors a dividend that yields 0.6% per year.
The company is now trading -13.7% away from its average analyst target price of $65.31 per share. The 13 analysts following the stock have set target prices ranging from $53.0 to $75.0, and on average give Bio-Techne Corp a rating of buy.
Over the last 12 months TECH shares have declined by -24.6%, which represents a difference of -40.5% when compared to the S&P 500. The stock's 52 week high is $80.95 per share and its 52 week low is $46.01. Based on Bio-Techne Corp's average net margin growth of 1.8% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 1,159,060 | 168,105 | 15 | -40.0 |
| 2023 | 1,136,702 | 285,263 | 25 | 0.0 |
| 2022 | 1,105,599 | 272,051 | 25 | 66.67 |
| 2021 | 931,032 | 140,410 | 15 | -51.61 |
| 2020 | 738,691 | 229,296 | 31 | 138.46 |
| 2019 | 714,006 | 96,072 | 13 |
